A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial

Cytoreductive nephrectomy has long been used to improve disease control in metastastic Renal Cell Carcinoma (mRCC). However, based on the results of the CARMENA and SURTIME trials, cytoreductive nephrectomy is no longer the standard of care in patients requiring upfront systemic treatment and it sho...

Descripción completa

Detalles Bibliográficos
Autores principales: de Velasco, Guillermo, Carril-Ajuria, Lucia, Guerrero-Ramos, Felix, Alonso-Gordoa, Teresa, Rodríguez-Moreno, Juan F., Carretero, Alberto, Martin-Soberon, Maricruz, de la Rosa-Kehrmann, Federico, Castellano, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720770/
https://www.ncbi.nlm.nih.gov/pubmed/33315988
http://dx.doi.org/10.18632/oncotarget.27807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720770/
https://www.ncbi.nlm.nih.gov/pubmed/33315988
http://dx.doi.org/10.18632/oncotarget.27807

Ejemplares similares